Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 42%
Buy 37%
Hold 16%
Sell 5%
Strong Sell 0%

Bulls say

Insulet is expected to continue its strong growth in the MedTech industry, with an estimated 20% revenue CAGR and 20% EPS growth. Despite recent product recalls, the company remains confident in maintaining its leadership position in the expanding tubeless category and has a strong governance model, making it a potentially attractive investment for shareholders in the long term. However, competition and short-term concerns may limit immediate stock performance.

Bears say

Insulet is facing several challenges that could negatively impact their stock performance in the future. These include competition within the insulin pump market, potential supply chain disruptions, and delays in international expansion. Additionally, recent voluntary medical device corrections and a potential slowdown in patient starts could also lead to slower revenue and profitability growth. The current valuation for Insulet may not fully account for these risks, making it a risky investment at this time.

Insulet (PODD) has been analyzed by 19 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 37% recommend Buy, 16% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 19 analysts, Insulet (PODD) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $235.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $235.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.